Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.64 |
| ▸ | ACLY | P53396 | 2/20 | 0.39 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL516979 | 0.97 | THRB (0.68) | THRBACLYTET2 | |
| Ammonia Solution, Strong SCHEMBL22686689 | 0.97 | THRB (0.68) | THRBACLYTET2 | |
| Ammonia Solution, Strong SCHEMBL28659421 | 0.97 | THRB (0.68) | THRBACLYTET2 | |
| Ammonia Solution, Strong SCHEMBL28554430 | 0.97 | THRB (0.68) | THRBACLYTET2 | |
| SCHEMBL28642164 | 0.97 | THRB (0.67) | THRBACLYTET2 | |
| SCHEMBL28659419 | 0.95 | THRB (0.71) | THRBACLYTET2 | |
| SCHEMBL11794828 | 0.95 | THRB (0.71) | THRBACLYTET2 | |
| SCHEMBL10799668 | 0.95 | THRB (0.71) | THRBACLYTET2 | |
| Ammonia Solution, Strong SCHEMBL517121 | 0.92 | THRB (0.59) | THRBACLY | |
| SCHEMBL5915248 | 0.89 | THRB (0.62) | THRBACLY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8487003-B2 | Modulation of plasma insulin, glucose, triglycerides, cholesterol and/or leptin using perfluorinated fatty acids | CXR BIOSCIENCES LIMITED (GB) | 2013-07-16 | — | — | US | disclosed |
| US-20120029079-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING FLUORINATED OR PERFLUORINATED CARBOXYLIC ACIDS | CXR BIOSCIENCES LIMITED (GB) | 2012-02-02 | — | — | US | disclosed |
| EP-2260842-A2 | Uses of perfluorinated carboylic acid derivatives for the manufacture of a medicament for the modulation of body mass | CXR Biosciences Limited (GB) | 2010-12-15 | — | — | EP | disclosed |
| US-20100240751-A1 | Methods | CXR BIOSCIENCES LIMITED | 2010-09-23 | — | — | US | disclosed |
| EP-1359906-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING FLUORINATED OR PERFLUORINATED CARBOXYLIC ACIDS | CXR BIOSCIENCES LTD (GB) | 2008-05-14 | — | — | EP | disclosed |
| EP-1875904-A1 | Methods | CXR BIOSCIENCES LIMITED (GB) | 2008-01-09 | — | — | EP | disclosed |
| EP-1745779-A2 | Uses of perfluorinated carboylic acid derivatives for the manufacture of a medicament for the modulation of body mass | CXR BIOSCIENCES LIMITED (GB) | 2007-01-24 | — | — | EP | disclosed |
| US-20060052451-A1 | Method | ELCOMBE CLIFFORD R | 2006-03-09 | — | — | US | disclosed |
| US-20050175639-A1 | Modulation of plasma insulin, glucose, triglycerides, cholesterol and/or leptin using perfluorinated fatty acids | CXR BIOSCIENCES LIMITED (GB) | 2005-08-11 | — | — | US | disclosed |
| EP-1534260-A2 | PERFLUORINATED FATTY ACIDS FOR THE TREATMENT OF OBESITY, DIABETES, HYPERLIPIDAEMIA, CANCER AND INFLAMMATION | CXR BIOSCIENCES LIMITED (GB) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004019927-A2 | PERFLUORINATED FATTY ACIDS FOR THE TREATMENT OF OBESITY, DIABETES, HYPERLIPIDAEMIA, CANCER AND INFLAMMATION | CXR BIOSCIENCES LIMITED (SC 211745) (GB) | 2004-03-11 | — | — | WO | disclosed |
| EP-1359906-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING FLUORINATED OR PERFLUORINATED CARBOXYLIC ACIDS | CXR BIOSCIENCES LIMITED (GB) | 2003-11-12 | — | — | EP | disclosed |
| WO-2002066028-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING FLUORINATED OR PERFLUORINATED CARBOXYLIC ACIDS | CXR BIOSCIENCES LIMITED (GB) | 2002-08-29 | — | — | WO | disclosed |